Provided by Tiger Trade Technology Pte. Ltd.

Pharvaris N.V.

31.10
-0.0200-0.06%
Post-market: 31.510.4100+1.32%16:27 EDT
Volume:754.99K
Turnover:23.73M
Market Cap:2.17B
PE:-10.39
High:31.96
Open:31.14
Low:31.09
Close:31.12
52wk High:43.25
52wk Low:20.65
Shares:69.86M
Float Shares:44.23M
Volume Ratio:1.20
T/O Rate:1.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9943
EPS(LYR):-3.4871
ROE:-70.46%
ROA:-42.32%
PB:6.45
PE(LYR):-8.92

Loading ...

Pharvaris' Rare Disease Drug Meets Primary, Secondary Goals in Phase 3 Trial

MT Newswires Live
·
Yesterday

Pharvaris’ deucrictibant shows efficacy in published Phase 3 HAE trial

TIPRANKS
·
Yesterday

Pharvaris Says Phase 3 RAPIDe-3 Trial Shows Oral Deucrictibant Speeds Symptom Relief in HAE Attacks

Reuters
·
Yesterday

Will Real World HAE Study Change Pharvaris Stock Narrative

Simply Wall St.
·
Oct 07

Pharvaris-Funded Real-World HAE Management Analysis Flags Treatment Satisfaction Gaps, Published in Advances in Therapy

Reuters
·
Oct 05

Pharvaris Currently Down 10 Consecutive Days, on Pace for Record Losing Streak

Dow Jones
·
Oct 02

Morgan Stanley Sticks to Its Buy Rating for Pharvaris (PHVS)

TIPRANKS
·
Sep 28

Pharvaris Insider Move Sparks Fresh Buzz on Wall Street

TIPRANKS
·
Sep 26

Insider Move at Pharvaris Sparks Fresh Investor Attention

TIPRANKS
·
Sep 25

Pharvaris Director Johannes Gerardus Christiaan Petrus Schikan Disposes of Common Shares Worth $28,952 in Cashless Option Exercise

Reuters
·
Sep 24

Top Pharvaris Executive Makes Attention-Grabbing Move With Company Stock

TIPRANKS
·
Sep 24

Pharvaris Chief Early Development Anne Lesage Disposes of USD 765,466 in Common Shares

Reuters
·
Sep 22

Pharvaris (PHVS) Gets a Buy from H.C. Wainwright

TIPRANKS
·
Sep 22

Top Pharvaris Executive Cashes In on Major Insider Stock Sale

TIPRANKS
·
Sep 18

Pharvaris Chief Commercial Officer Wim Souverijns Sells USD 1.02 Million in Common Shares

Reuters
·
Sep 17

Morgan Stanley Reaffirms Their Buy Rating on Pharvaris (PHVS)

TIPRANKS
·
Sep 14

Pharvaris Director Robert Glassman Disposes of Common Shares Worth $300,396

Reuters
·
Sep 12

BioCryst Pharmaceuticals Faces Competitive Pressure in Hereditary Angioedema Treatment, RBC Says

MT Newswires Live
·
Sep 10

Analysts Conflicted on These Healthcare Names: Xeris Pharmaceuticals (XERS) and Pharvaris (PHVS)

TIPRANKS
·
Sep 10

Pharvaris Price Target Raised to $65.00/Share from $50.00 by Leerink Partners

Dow Jones
·
Sep 10